Your browser doesn't support javascript.
Primary care provider-reported prevalence of vaccine and polyethylene glycol allergy in Canada.
Abrams, Elissa M; Greenhawt, Matthew; Shaker, Marcus; Kosowan, Leanne; Singer, Alexander G.
  • Abrams EM; Section of Allergy and Clinical Immunology, Department of Pediatrics, University of Manitoba, Winnipeg, Canada; Division of Allergy and Immunology, Department of Pediatrics, University of British Columbia, Vancouver, Canada. Electronic address: elissa.abrams@gmail.com.
  • Greenhawt M; Section of Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.
  • Shaker M; Section of Allergy and Immunology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
  • Kosowan L; Department of Family Medicine, University of Manitoba, Winnipeg, Canada.
  • Singer AG; Department of Family Medicine, University of Manitoba, Winnipeg, Canada.
Ann Allergy Asthma Immunol ; 127(4): 446-450.e1, 2021 10.
Article in English | MEDLINE | ID: covidwho-1230347
ABSTRACT

BACKGROUND:

The coronavirus disease 2019 pandemic has highlighted the importance of accurate capture of vaccine, and vaccine component, allergy. There remains a gap in the prevalence literature from the perspective of direct primary care provider (PCP) reporting at a population level.

OBJECTIVE:

To determine the prevalence of PCP-documented vaccine and polyethylene glycol (PEG) allergy using electronic medical record data from the Canadian Primary Care Sentinel Surveillance Network.

METHODS:

Retrospective cohort study using the Canadian Primary Care Sentinel Surveillance Network repository. Machine learning algorithms were applied to evaluate for vaccine allergy documentation, and Anatomic Therapeutic Chemical codes were used for PEG allergy or allergy to common injectable medications containing PEG (CIMCP).

RESULTS:

The prevalence of PCP-documented vaccine allergy in Canada was 0.037% (395/1,055,677) and of PEG allergy was 0.0009% (10/1,055,677). In total, 0.01% of patients had a documented allergy to either PEG or CIMCP (135/1,055,677). None of the patients with PEG allergy had a documented allergy to a CIMCP. Patients with vaccine allergy and PEG allergy were significantly more likely to have other atopic comorbidities, including asthma (P < .001 for both), eczema (P < .001 and P = .001, respectively), rhinitis (P = .002 and P < .001, respectively), and food allergy (P < .001 for both). Significantly higher rates of depression (P < .001 and P < .001, respectively) and anxiety (P = .003 and P < .001, respectively) were found in those with vaccine allergy, or PEG allergy, than those without vaccine allergy or PEG allergy.

CONCLUSION:

This is the first study to estimate the prevalence of vaccine and PEG allergy in a national cohort that uses PCP documentation, revealing a low reported rate of vaccine allergy and PEG allergy.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Polyethylene Glycols / Vaccines / Hypersensitivity / Hypersensitivity, Immediate Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Ann Allergy Asthma Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Polyethylene Glycols / Vaccines / Hypersensitivity / Hypersensitivity, Immediate Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Ann Allergy Asthma Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article